Overview

Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
0
Participant gender:
All
Summary
This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of cancers.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
ZymoGenetics
Criteria
Inclusion Criteria:

- 18 years and older with stage 4 metastatic malignant melanoma or stage 4 metastatic
kidney cancer

- ECOG status of 0 or 1

- Patients must have adequate liver, kidney and bone marrow function

Exclusion Criteria:

- Known ocular melanoma

- Suspected or confirmed brain metastases

- Patient cannot have had a bone marrow transplant